bluebird bio, Inc. (BLE.F)
Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
As of 05:13PM CEST. Market open.
| Previous close | 15.90 |
| Open | 15.85 |
| Bid | 0.00 x 12000 |
| Ask | 0.00 x 12000 |
| Day's range | 15.85 - 15.90 |
| 52-week range | 15.31 - 49.99 |
| Volume | |
| Avg. volume | 103 |
| Market cap | 1.075B |
| Beta (5Y monthly) | 1.33 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -9.91 |
| Earnings date | 03 Nov 2022 - 07 Nov 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 22.80 |
- Business Wire
bluebird bio Reports Second Quarter 2022 Financial Results and Highlights Operational Progress
SOMERVILLE, Mass, August 04, 2022--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today reported financial results and business highlights for the second quarter ended June 30, 2022, and shared recent operational progress.
- Simply Wall St.
What Kind Of Shareholders Hold The Majority In bluebird bio, Inc.'s (NASDAQ:BLUE) Shares?
If you want to know who really controls bluebird bio, Inc. ( NASDAQ:BLUE ), then you'll have to look at the makeup of...
- Business Wire
FDA Advisory Committee Unanimously Supports beti-cel Gene Therapy for People with beta-thalassemia Who Require Regular Red Blood Cell Transfusions
SOMERVILLE, Mass., June 10, 2022--bluebird bio, Inc. (Nasdaq: BLUE) today announced the outcome of the U.S. Food and Drug Administration’s (FDA) Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) discussion of betibeglogene autotemcel (beti-cel) for the treatment of people with beta-thalassemia who require regular red blood cell (RBC) transfusions.
© 2022 Yahoo. All rights reserved.
